연구성과로 돌아가기

2023 연구성과별 연구자 정보 (37 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Lee, Jeong-Ok Lee, JO 10 Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Seongnam, South Korea J-5603-2012 Lee, Jong-Seok kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Jo, Jae-Cheol Jo, JC 11 Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea CAE-9453-2022 Jo, Jae-Cheol kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Yang, Deok-Hwan Yang, DH 12 교신저자 Chonnam Natl Univ, Med Sch, Hwasun, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Yang, Deok-Hwan Yang, DH 12 교신저자 Hwasun Hosp, Hwasun, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Yang, Deok-Hwan Yang, DH 12 교신저자 Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, 322 Seoyang Ro, Hwasun 58128, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Yang, Deok-Hwan Yang, DH 12 교신저자 Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Choi, Seung Won Choi, SW 1 Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, 81 Irwon Ro, Seoul 06351, South Korea nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Jung, Hyun Ae Jung, HA 2 Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 81 Irwon Ro, Seoul 06351, South Korea nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Cho, Hee-Jin Cho, HJ 3 Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Kim, Tae Min Kim, TM 4 Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Dept Internal Med, Seoul, South Korea B-9921-2013 Kim, Tae 0000-0001-6145-4426 Kim, Tae Min nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Park, Chul-Kee Park, CK 5 Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea J-5499-2012 Park, Chul-Kee 0000-0002-2350-9876 Park, Chul-Kee nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Nam, Do-Hyun Nam, D 6 교신저자 Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, 81 Irwon Ro, Seoul 06351, South Korea nsnam@ssku.edu;sehoon.lee@samsung.com;
A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification Lee, Se-Hoon Lee, SH 7 교신저자 Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 81 Irwon Ro, Seoul 06351, South Korea nsnam@ssku.edu;sehoon.lee@samsung.com;
A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye Eom, Youngsub Eom, Y 1 Korea Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea 0000-0001-9475-4409 Eom, Youngsub hyomkim@kumc.or.kr;
A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye Eom, Youngsub Eom, Y 1 Korea Univ, Ansan Hosp, Dept Ophthalmol, Seoul, Gyeonggido, South Korea 0000-0001-9475-4409 Eom, Youngsub hyomkim@kumc.or.kr;
페이지 이동: